Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of [1,4']Bipiperidinyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.50 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5238623 | 1.00 | HTR6 (0.50) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL5235217 | 1.00 | HTR6 (0.50) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL3571227 | 1.00 | HTR6 (0.50) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL5322658 | 1.00 | HTR6 (0.50) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| [1,4']Bipiperidinyl SCHEMBL2250608 | 1.00 | HTR6 (0.50) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| [1,4']Bipiperidinyl SCHEMBL352141 | 0.97 | HTR6 (0.52) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL6952706 | 0.97 | HTR6 (0.52) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL15232249 | 0.97 | HTR6 (0.52) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| [1,4']Bipiperidinyl SCHEMBL42685 | 0.97 | HTR6 (0.52) | HTR6L3MBTL3L3MBTL1HPGDKMT2A | |
| SCHEMBL3159634 | 0.97 | HTR6 (0.52) | HTR6L3MBTL3L3MBTL1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185450-B | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2022-03-11 | — | — | CN | claimed |
| CN-113185450-A | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2021-07-30 | — | — | CN | claimed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| US-11760741-B2 | Pro-drugs of eliglustat | KASHIV BIOSCIENCES, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| CN-114450284-A | 6, 7-dihydro-5H-pyrido [2,3-C ] pyridazine derivatives and related compounds as BCL-XL protein inhibitors and pro-apoptotic agents for the treatment of cancer | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| CN-113185450-B | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-113185450-B | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-113185450-A | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-113185450-A | Palladium removal method for irinotecan hydrochloride intermediate | 江苏海洋大学 | 2021-07-30 | — | — | CN | disclosed |
| US-10166226-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| WO-2018178938-A1 | CGRP RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| US-20170239236-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9688660-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-27 | — | — | US | disclosed |
| US-20170121311-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| WO-2017072723-A1 | CGRP RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-05-04 | — | — | WO | disclosed |
| CN-102260272-B | A kind of method preparing U 101440E | YANGTZE RIVER PHARMACEUTICAL CO., LTD. (CN) | 2016-01-13 | — | — | CN | disclosed |
| CN-102260272-A | Method for preparing irinotecan hydrochloride | — | 2011-11-30 | — | — | CN | disclosed |
| EP-0976733-B1 | PROCESS FOR PRODUCING 1-CHLOROCARBONYL-4-PIPERIDINOPIPERIDINE OR HYDROCHLORIDE THEREOF | YAKULT HONSHA KK (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6147215-A | Process for producing 1-chlorocarbonyl-4-piperidinopiperidine or hydrochloride thereof | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0976733-A1 | PROCESS FOR PRODUCING 1-CHLOROCARBONYL-4-PIPERIDINOPIPERIDINE OR HYDROCHLORIDE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239236-A1 | CGRP Receptor Antagonists | CALCRL, CNR1, GALR1 | HTR6 213/4885HRH3 472/4885L3MBTL3 4750/4885 |
| US-20170121311-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CNR1, GALR1 | HTR6 213/4885HRH3 472/4885L3MBTL3 4750/4885 |
| US-10166226-B2 | CGRP receptor antagonists | CALCRL, CNR1, GALR1 | HTR6 213/4885HRH3 472/4885L3MBTL3 4750/4885 |
| US-11760741-B2 | Pro-drugs of eliglustat | GCG, GLP1R, PROKR1 | HTR6 919/4885HRH3 419/4885L3MBTL3 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.